D Verthelyi

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi request reprint Disassociation of sex hormone levels and cytokine production in SLE patients
    D Verthelyi
    Retroviral Immunology Section, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Lupus 10:352-8. 2001
  2. pmc Use of thermolytic protective groups to prevent G-tetrad formation in CpG ODN type D: structural studies and immunomodulatory activity in primates
    Montserrat Puig
    Laboratory of Immunology, Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Nucleic Acids Res 34:6488-95. 2006
  3. ncbi request reprint Sex hormones as immunomodulators in health and disease
    D Verthelyi
    Retroviral Immunology Section, Center for Biologics Evaluation and Research, Food and Drug Administration, Building 29A, Rm 3 D 2, Bethesda, MD 20892, USA
    Int Immunopharmacol 1:983-93. 2001
  4. ncbi request reprint Female's heightened immune status: estrogen, T cells, and inducible nitric oxide synthase in the balance
    Daniela Verthelyi
    Laboratory of Immunology, Division of Therapeutic Proteins, Center for Drug Evaluation and Review, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Endocrinology 147:659-61. 2006
  5. ncbi request reprint Differential signaling by CpG DNA in DCs and B cells: not just TLR9
    Daniela Verthelyi
    Division of Therapeutic Proteins, Center for Biologics Research and Evaluation, Food and Drug Administration, Bldg 29A Rm 3B19, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Trends Immunol 24:519-22. 2003
  6. ncbi request reprint CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection
    Daniela Verthelyi
    Section of Retroviral Immunology and Division of Bacterial, Parasitic, and Allergenic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    J Immunol 170:4717-23. 2003
  7. ncbi request reprint Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs
    D Verthelyi
    Section of Retroviral Research, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    J Immunol 166:2372-7. 2001
  8. ncbi request reprint Response of peripheral blood mononuclear cells from lupus patients to stimulation by CpG oligodeoxynucleotides
    R A Zeuner
    Center for Biologics Evaluation and Research Food and Drug Administration, Bethesda, Maryland, USA
    Rheumatology (Oxford) 42:563-9. 2003
  9. pmc Regulatory role of suppressive motifs from commensal DNA
    N Bouladoux
    Mucosal Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Mucosal Immunol 5:623-34. 2012
  10. ncbi request reprint Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates
    Daniela Verthelyi
    Division of Therapeutic Proteins, Food and Drug Administration, Building 29A Room 3B19, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Clin Immunol 109:64-71. 2003

Collaborators

  • Yasmine Belkaid
  • D M Klinman
  • Richard T Kenney
  • M Petri
  • Robert A Seder
  • Ken J Ishii
  • Cynthia Leifer
  • Hiroshi Yamada
  • J D Lifson
  • Fumihiko Takeshita
  • Montserrat Puig
  • Andrzej Grajkowski
  • Joao A Pedras-Vasconcelos
  • Mayda Gursel
  • Rainald A Zeuner
  • Joao Pedras-Vasconcelos
  • Vivian Wang
  • Cristina Ausín
  • Serge L Beaucage
  • N Bouladoux
  • David Goucher
  • Eugene D Ponomarev
  • Nora Katsenelson
  • Barbara Flynn
  • David L Sacks
  • R A Zeuner
  • Susana Mendez
  • Ihsan Gursel
  • V Nagarajan
  • L M dos Santos
  • J R Grainger
  • M G Kann
  • J A Hall
  • Candie Wolbert
  • Mikhail Ovanesov
  • Christian Sauder
  • Howard Mostowski
  • Sunita Kanswal
  • Bonnie N Dittel
  • Katarzyna Maresz
  • Mustafa Akkoyunlu
  • Leah P Shriver
  • Leonardo H Tonelli
  • Shuichi Ito
  • Malgorzata Boczkowska
  • Sonja Hess
  • G Illei
  • Sylvie Bertholet
  • M Gursel
  • C Yarboro
  • Khaled Tabbara
  • Martin J Lizak

Detail Information

Publications28

  1. ncbi request reprint Disassociation of sex hormone levels and cytokine production in SLE patients
    D Verthelyi
    Retroviral Immunology Section, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Lupus 10:352-8. 2001
    ..Thus, while it remains possible that increased E2 and reduced DHEAS levels in lupus patients may help induce cytokine abnormalities early in disease, the subsequent cytokine imbalance does not correlate with sex hormone levels...
  2. pmc Use of thermolytic protective groups to prevent G-tetrad formation in CpG ODN type D: structural studies and immunomodulatory activity in primates
    Montserrat Puig
    Laboratory of Immunology, Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Nucleic Acids Res 34:6488-95. 2006
    ..This technology fosters the development of more efficient immunotherapeutic oligonucleotide formulations for the treatment of allergies, cancer and infectious diseases...
  3. ncbi request reprint Sex hormones as immunomodulators in health and disease
    D Verthelyi
    Retroviral Immunology Section, Center for Biologics Evaluation and Research, Food and Drug Administration, Building 29A, Rm 3 D 2, Bethesda, MD 20892, USA
    Int Immunopharmacol 1:983-93. 2001
    ..Understanding the physiology of the interaction between sex hormones and immune function and its potential pathological consequences may provide insight into the autoimmune diseases and new directions for their treatment...
  4. ncbi request reprint Female's heightened immune status: estrogen, T cells, and inducible nitric oxide synthase in the balance
    Daniela Verthelyi
    Laboratory of Immunology, Division of Therapeutic Proteins, Center for Drug Evaluation and Review, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Endocrinology 147:659-61. 2006
  5. ncbi request reprint Differential signaling by CpG DNA in DCs and B cells: not just TLR9
    Daniela Verthelyi
    Division of Therapeutic Proteins, Center for Biologics Research and Evaluation, Food and Drug Administration, Bldg 29A Rm 3B19, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Trends Immunol 24:519-22. 2003
    ..The different signaling complexes assembled might impact on the affinity with which CpG ODNs signal to TLR9 or activate additional pathways that lead to distinct immune responses...
  6. ncbi request reprint CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection
    Daniela Verthelyi
    Section of Retroviral Immunology and Division of Bacterial, Parasitic, and Allergenic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    J Immunol 170:4717-23. 2003
    ..These findings support the clinical development of CpG ODNs as immunoprotective agents in normal and HIV-infected patients...
  7. ncbi request reprint Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs
    D Verthelyi
    Section of Retroviral Research, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    J Immunol 166:2372-7. 2001
    ..The distinct immunostimulatory properties of K and D ODN can improve the design of CpG-based products to achieve specific therapeutic goals...
  8. ncbi request reprint Response of peripheral blood mononuclear cells from lupus patients to stimulation by CpG oligodeoxynucleotides
    R A Zeuner
    Center for Biologics Evaluation and Research Food and Drug Administration, Bethesda, Maryland, USA
    Rheumatology (Oxford) 42:563-9. 2003
    ..This study characterizes the in vitro response of peripheral blood mononuclear cells (PBMC) from SLE patients to CpG DNA...
  9. pmc Regulatory role of suppressive motifs from commensal DNA
    N Bouladoux
    Mucosal Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Mucosal Immunol 5:623-34. 2012
    ..Further, our findings suggest that the endogenous regulatory capacity of DNA motifs enriched in some commensal bacteria could be exploited for therapeutic purposes...
  10. ncbi request reprint Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates
    Daniela Verthelyi
    Division of Therapeutic Proteins, Food and Drug Administration, Building 29A Room 3B19, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Clin Immunol 109:64-71. 2003
    ..In vivo studies in nonhuman primates indicate that proinflammatory or humoral immune responses can be selectively facilitated by judicious use of these distinct types of ODN...
  11. ncbi request reprint Immunotherapy with CpG oligonucleotides and antibodies to TNF-alpha rescues neonatal mice from lethal arenavirus-induced meningoencephalitis
    Joao A Pedras-Vasconcelos
    Laboratory of Immunology, Division of Therapeutic Proteins, Office of Biotechnology, Center for Drug Evaluation and Review, FDA, Bethesda, MD 20892, USA
    J Immunol 180:8231-40. 2008
    ..To our knowledge, this is the first demonstration of the use of innate immune modulators plus Abs to TNF-alpha as therapeutics for a lethal neurotropic viral infection...
  12. ncbi request reprint Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion
    Nora Katsenelson
    Laboratory of Bacterial Polysaccharides, Division of Bacterial Parasitic and Allergenic Products, US Food and Drug Administration, Rockville, MD 20852 1448, USA
    Eur J Immunol 37:1785-95. 2007
    ..Thus, CpG ODN-induced increase in TACI expression is likely to play an important role in Ig secretion following activation of B lymphocytes through TLR9...
  13. ncbi request reprint Adjuvant properties of CpG oligonucleotides in primates
    Daniela Verthelyi
    Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA
    Methods Mol Med 127:139-58. 2006
    ..This work examines the progress in utilizing CpG ODN as adjuvants in conventional and DNA vaccines...
  14. ncbi request reprint CpG oligodeoxynucleotides as vaccine adjuvants in primates
    Daniela Verthelyi
    Divisions of Viral Products and Bacterial, Parasitic, and Allergenic Products, Center for Biologics Evaluation and Research Food and Drug Administration, Bethesda, MD 20892, USA
    J Immunol 168:1659-63. 2002
    ..These findings indicate that rhesus macaques provide a useful model for studying the in vivo activity of human CpG motifs, and that ODN expressing these motifs act as strong immune adjuvants...
  15. pmc Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs
    Barbara Flynn
    Division of Therapeutic Proteins, Center for Drug Evaluation and Review, Food and Drug Administration, Washington, D C, USA
    Infect Immun 73:4948-54. 2005
    ..major treatment. Together, these findings support the development of clinical studies to assess the use of CpG ODN types D/A as immunoprotective and therapeutic agents...
  16. pmc Thermolytic CpG-containing DNA oligonucleotides as potential immunotherapeutic prodrugs
    Andrzej Grajkowski
    Laboratory of Chemistry, Center for Drug Evaluation and Research, Food and Drug Administration 8800 Rockville Pike, Bethesda, MD 20892, USA
    Nucleic Acids Res 33:3550-60. 2005
    ....
  17. ncbi request reprint Use of CpG oligodeoxynucleotides as immune adjuvants
    Dennis M Klinman
    Section of Retroviral Immunology, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Immunol Rev 199:201-16. 2004
    ..Ongoing clinical studies indicate that CpG ODNs are safe and well tolerated when administered as adjuvants to humans, and in some cases, they increase vaccine-induced immune responses...
  18. ncbi request reprint CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques
    Daniela Verthelyi
    Division of Therapeutic Proteins, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    AIDS 18:1003-8. 2004
    ..Although HBV vaccination is recommended to all HIV-positive patients, its efficacy in these patients is reduced...
  19. ncbi request reprint CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells
    Mayda Gursel
    Section of Retroviral Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda 20892, USA
    Eur J Immunol 32:2617-22. 2002
    ..Since D type CpG motifs are present in bacterial and viral DNA, the maturation of monocytes into functional DC may reflect a physiologic response that can be harnessed therapeutically through the use of CpG ODN...
  20. ncbi request reprint Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides
    Cynthia A Leifer
    Section of Retroviral Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    J Immunother 26:313-9. 2003
    ..A mixture of ODNs with complementary activities induced significantly broader stimulation of donor PBMCs than any single ODN, providing a rational basis for proceeding into clinical trials with such a mixture...
  21. pmc Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability
    Susana Mendez
    Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Infect Immun 71:5121-9. 2003
    ..Our results suggest that immune modulation using CpG ODNs might be a practical approach to improving the safety of a highly effective live vaccine that has already been widely applied...
  22. ncbi request reprint CpG DNA: recognition by and activation of monocytes
    Dennis M Klinman
    Retroviral Immunology Section, Center for Biologics Evaluation and Research, FDA, Bldg 29A Rm 3 D 10, Bethesda, MD 20892, USA
    Microbes Infect 4:897-901. 2002
    ..ODNs of the "K"-type interact with Toll-like receptor 9 and induce monocytes to proliferate and secrete IL-6. In contrast, "D"-type ODNs trigger monocytes to differentiate into mature dendritic cells...
  23. ncbi request reprint Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide
    Mayda Gursel
    Section of Retroviral Research, Center for Biologics Evaluation and Research, Food and Drug Administration, Bldg 29A Rm 3D10, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Leukoc Biol 71:813-20. 2002
    ..Thus, different types of CpG ODN have distinct and in some cases incompatible effects on the same cells, a finding with important implications for the therapeutic use of these agents...
  24. ncbi request reprint CpG oligodeoxynucleotides protect newborn mice from a lethal challenge with the neurotropic Tacaribe arenavirus
    Joao A Pedras-Vasconcelos
    Division of Therapeutic Proteins, Office of Biotechnology Products, Center for Drug Evaluation and Research, Federal Drug Administration, Bethesda, MD 20892, USA
    J Immunol 176:4940-9. 2006
    ..To our knowledge, this is the first study assessing the mechanisms by which CpG ODN can protect mice from a neurotropic viral infection...
  25. ncbi request reprint Design and development of thermolytic DNA oligonucleotide prodrugs
    Andrzej Grajkowski
    Laboratory of Chemistry, Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Ann N Y Acad Sci 1058:26-38. 2005
    ....
  26. ncbi request reprint GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis
    Eugene D Ponomarev
    Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI 53201, USA
    J Immunol 178:39-48. 2007
    ..These data also demonstrate that GM-CSF is a critical Th1 cell-derived cytokine required for the initiation of CNS inflammation associated with EAE, and likely MS...
  27. ncbi request reprint Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis
    Rainald A Zeuner
    II Medical Clinic, University of Kiel, Kiel, Germany
    Arthritis Rheum 48:1701-7. 2003
    ..To examine whether systemic administration of immunostimulatory and immunosuppressive oligodeoxynucleotides (ODNs) alter host susceptibility to inflammatory arthritis...
  28. ncbi request reprint Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides
    Rainald A Zeuner
    Center for Biologics Evaluation and Research, FDA, Bethesda, Maryland, and Christian Albrechts University Kiel, Kiel, Germany
    Arthritis Rheum 46:2219-24. 2002
    ..We examined whether synthetic oligodeoxynucleotides (ODN) that suppress CpG-induced immune responses prevent CpG-induced arthritis...